Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Zevra Therapeutics ( (ZVRA) ) just unveiled an update.
On March 13, 2026, Zevra Therapeutics agreed to sell its serdexmethylphenidate (SDX) portfolio, including AZSTARYS and KP1077, to Commave Therapeutics for $50 million while also resolving ongoing litigation in Delaware tied to a 2019 collaboration and license deal. The transaction transfers Zevra’s SDX-related assets and grants Commave a perpetual license under Zevra’s remaining SDX patents and know-how, with the parties terminating their prior AZSTARYS license agreement and mutually releasing claims.
The asset sale, effective March 13, 2026, brings Zevra a staged cash payment and eliminates legal overhang as both companies move to dismiss the lawsuit with prejudice. On March 12, 2026, Zevra also fully repaid approximately $63 million outstanding under its term loan facility, terminating the credit agreement and releasing associated liens, which leaves the company debt-free and enhances its financial and strategic flexibility to concentrate on its rare disease franchise.
The most recent analyst rating on (ZVRA) stock is a Buy with a $23.00 price target. To see the full list of analyst forecasts on Zevra Therapeutics stock, see the ZVRA Stock Forecast page.
Spark’s Take on ZVRA Stock
According to Spark, TipRanks’ AI Analyst, ZVRA is a Neutral.
The score is mainly held back by mixed financial quality—strong reported profitability and an improved balance sheet, but ongoing operating losses and negative/free cash flow. Technicals are supportive with a strong uptrend, though overbought signals add near-term risk, while valuation looks favorable on a low P/E and the earnings call was broadly positive on MIPLYFFA momentum and expansion progress.
To see Spark’s full report on ZVRA stock, click here.
More about Zevra Therapeutics
Zevra Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people living with rare diseases. The company’s strategy centers on geographic expansion, progressing a late-stage pipeline, and leveraging U.S. commercialization of its lead treatment for Niemann-Pick disease type C to validate its ability to advance therapies from development to market.
Zevra aims to broaden access to rare disease therapies while executing a disciplined strategic plan guided by patient centricity, integrity, accountability, innovation, and courage. Its rare disease focus and existing commercial platform position the company to pursue additional milestones and long-term value creation within the specialized orphan-drug market.
Average Trading Volume: 1,103,874
Technical Sentiment Signal: Buy
Current Market Cap: $585.9M
For an in-depth examination of ZVRA stock, go to TipRanks’ Overview page.